These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37946834)

  • 1. Retracted: A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy.
    And Biomechanics AB
    Appl Bionics Biomech; 2023; 2023():9829630. PubMed ID: 37946834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy.
    Bian J; Niu Y; Ma Y; Chen F; Ma N
    Appl Bionics Biomech; 2022; 2022():8537966. PubMed ID: 35126664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retracted: Differentially Expressed Genes in Nasopharyngeal Carcinoma Tissues and Their Correlation with Recurrence and Metastasis of Nasopharyngeal Carcinoma.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9781420. PubMed ID: 37416142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retracted: Application of Artificial Intelligence in Radiotherapy of Nasopharyngeal Carcinoma with Magnetic Resonance Imaging.
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9825710. PubMed ID: 38094840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
    Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
    Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
    Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
    Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retracted] miR‑639 is associated with advanced cancer stages and promotes proliferation and migration of nasopharyngeal carcinoma.
    Wang YH; Yin YW; Zhou H; Cao YD
    Oncol Lett; 2024 Feb; 27(2):76. PubMed ID: 38192678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.
    Wang S; Chen S; Zhong Q; Liu Y
    J Cancer Res Clin Oncol; 2023 May; 149(5):2071-2079. PubMed ID: 35876949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retracted: Identification of Key Genes in Nasopharyngeal Carcinoma Based on Bioinformatics Analysis.
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9836790. PubMed ID: 38074350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retracted: Demographics and Economic Burden of Nasopharyngeal Carcinoma Inpatients.
    International BR
    Biomed Res Int; 2023; 2023():9850320. PubMed ID: 38188831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: USP21 Promotes the Progression of Nasopharyngeal Carcinoma by Regulating FOXM1.
    International SC
    Stem Cells Int; 2024; 2024():9763687. PubMed ID: 38298234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retracted: Effects of Cisplatin Combined with Metformin on Proliferation and Apoptosis of Nasopharyngeal Carcinoma Cells.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9856726. PubMed ID: 37475936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retracted: Downregulation of SHCBP1 Inhibits Proliferation, Migration, and Invasion in Human Nasopharyngeal Carcinoma Cells.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9812746. PubMed ID: 37387977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
    Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
    Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: Prediction of Changes in Tumor Regression during Radiotherapy for Nasopharyngeal Carcinoma by Using the Computed Tomography-Based Radiomics.
    Imaging CMM
    Contrast Media Mol Imaging; 2023; 2023():9809608. PubMed ID: 37547642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracted: Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9798503. PubMed ID: 37416222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.